Biotechnology company, Prima Biomed is looking for its silver lining with the acquisition of French biopharmaceutical company Immutep SA for $US28 million.
Biotechnology company, Prima Biomed is looking to revive its fortunes with the acquisition of French biopharmaceutical company Immutep SA for $US28 million ($31.9 million).
The company, which has had a chequered history with little positive results with its ovarian cancer immuno-therapy drugs CVac, will receive royalty and milestone payments from Immutep’s partners, pharmaceutical companies GlaxoSmithKline, Novartis’ CoStim and Eddingpharm.
